MX2019014784A - Tratamiento para la migra?a. - Google Patents
Tratamiento para la migra?a.Info
- Publication number
- MX2019014784A MX2019014784A MX2019014784A MX2019014784A MX2019014784A MX 2019014784 A MX2019014784 A MX 2019014784A MX 2019014784 A MX2019014784 A MX 2019014784A MX 2019014784 A MX2019014784 A MX 2019014784A MX 2019014784 A MX2019014784 A MX 2019014784A
- Authority
- MX
- Mexico
- Prior art keywords
- leucine
- migraine
- treatment
- acetyl
- subject
- Prior art date
Links
- 208000019695 Migraine disease Diseases 0.000 title abstract 3
- 206010027599 migraine Diseases 0.000 title abstract 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 2
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 abstract 2
- 229960000669 acetylleucine Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un primer aspecto de la invención se relaciona con la leucina, acetil-leucina o una sal farmacéuticamente aceptable de la misma, para usarse en el tratamiento o prevención de una migraña o uno o más síntomas asociados con esta. Un segundo aspecto de la invención se relaciona con un método de tratamiento o prevención de una migraña o uno o más síntomas asociados con esta, en un sujeto, el método comprende administrar al sujeto una cantidad terapéuticamente o profilácticamente efectiva de leucina, acetil-leucina o una sal farmacéuticamente aceptable de esta.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1709459.0A GB201709459D0 (en) | 2017-06-14 | 2017-06-14 | Treatment for migraine |
| PCT/IB2018/054676 WO2018229738A1 (en) | 2017-06-14 | 2018-06-25 | Treatment for migraine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019014784A true MX2019014784A (es) | 2021-11-16 |
| MX387909B MX387909B (es) | 2025-03-19 |
Family
ID=59358204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014784A MX387909B (es) | 2017-06-14 | 2018-06-25 | Tratamiento para la migra?a |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11471434B2 (es) |
| EP (1) | EP3638370B1 (es) |
| JP (1) | JP7130739B2 (es) |
| KR (1) | KR102594130B1 (es) |
| CN (1) | CN111093772B (es) |
| AU (1) | AU2018284330B2 (es) |
| CY (1) | CY1123860T1 (es) |
| DK (1) | DK3638370T3 (es) |
| ES (1) | ES2847169T3 (es) |
| GB (1) | GB201709459D0 (es) |
| HR (1) | HRP20210108T1 (es) |
| HU (1) | HUE053089T2 (es) |
| IL (1) | IL271211B2 (es) |
| LT (1) | LT3638370T (es) |
| MA (1) | MA49396B1 (es) |
| MD (1) | MD3638370T2 (es) |
| MX (1) | MX387909B (es) |
| PL (1) | PL3638370T3 (es) |
| PT (1) | PT3638370T (es) |
| RS (1) | RS61481B1 (es) |
| SG (1) | SG11201912146RA (es) |
| SI (1) | SI3638370T1 (es) |
| SM (1) | SMT202100037T1 (es) |
| WO (1) | WO2018229738A1 (es) |
| ZA (1) | ZA201908087B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3091353A1 (en) | 2018-02-15 | 2019-08-22 | Intrabio Ltd | Therapeutic agents for treating restless legs syndrome |
| WO2020115715A1 (en) * | 2018-12-06 | 2020-06-11 | Intrabio Ltd. | Deuterated analogs of acetyl-leucine |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8701662L (sv) * | 1987-04-22 | 1988-10-23 | Gelder Nico M Van | Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna |
| US20040127501A1 (en) * | 2002-09-24 | 2004-07-01 | Zhengming Chen | Therapeutic agents useful for treating pain |
| US20060063827A1 (en) | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| MY142655A (en) * | 2003-06-12 | 2010-12-15 | Euro Celtique Sa | Therapeutic agents useful for treating pain |
| PT1641775E (pt) * | 2003-07-03 | 2009-04-23 | Euro Celtique Sa | Derivados de 2-piridina-alcino úteis para o tratamento da dor |
| ES2327684T3 (es) * | 2003-07-24 | 2009-11-02 | Euro-Celtique S.A. | Compuestos heteroaril-tetrahidropiridilo utiles para el tratamiento o la prevencion del dolor. |
| PL1664041T3 (pl) * | 2003-09-22 | 2008-12-31 | Euro Celtique Sa | Przydatne do leczenia bólu związki fenylowo-karboksyamidowe |
| PT1664016E (pt) * | 2003-09-22 | 2008-12-29 | Euro Celtique Sa | Agentes terapêuticos úteis para tratamento da dor |
| AP2006003678A0 (en) * | 2003-12-30 | 2006-08-31 | Euro Celtique Sa | Piperazines useful for treating pain |
| FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| TN2010000251A1 (fr) | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| WO2011162409A1 (en) * | 2010-06-22 | 2011-12-29 | Shionogi & Co., Ltd. | Compounds having trpv1 antagonistic activity and uses thereof |
| LT2588130T (lt) | 2010-06-25 | 2016-12-12 | Shire Human Genetic Therapies, Inc. | Terapinės priemonės pristatymas cns |
| JP6092113B2 (ja) * | 2010-11-09 | 2017-03-08 | マンカインド コーポレイション | セロトニン受容体アゴニストおよびジケトピペラジンを含む偏頭痛治療のための組成物 |
| AU2012293417A1 (en) * | 2011-08-10 | 2013-05-02 | Purdue Pharma L.P. | TRPV1 antagonists including dihydroxy substituent and uses thereof |
| KR102413754B1 (ko) | 2016-04-19 | 2022-06-27 | 인트라바이오 리미티드 | 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염 |
| MA55947A (fr) | 2016-08-11 | 2022-03-23 | Intrabio Ltd | Compositions pharmaceutiques et utilisations dirigées vers des troubles d'entreposage lysosomial |
| PL3416631T3 (pl) | 2016-08-11 | 2019-11-29 | Intrabio Ltd | Środki terapeutyczne do leczenia chorób neurodegeneracyjnych |
| PT3600276T (pt) | 2017-03-28 | 2023-07-11 | Intrabio Ltd | Beta-histina, ou um seu sal farmaceuticamente aceitável, e um inibidor da monoamina oxidase, para utilização no tratamento ou prevenção de um ou mais sintomas de vertigem num indivíduo |
| CN111542314B (zh) | 2017-10-18 | 2023-11-24 | 内在生物技术有限公司 | 神经退行性疾病的治疗剂 |
| US12458614B2 (en) | 2017-10-18 | 2025-11-04 | Intrabio Ltd | Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders |
| CA3091353A1 (en) | 2018-02-15 | 2019-08-22 | Intrabio Ltd | Therapeutic agents for treating restless legs syndrome |
| WO2020115715A1 (en) | 2018-12-06 | 2020-06-11 | Intrabio Ltd. | Deuterated analogs of acetyl-leucine |
| IL321899A (en) | 2019-03-02 | 2025-09-01 | Intrabio Ltd | Leucine, acetyl leucine and related analogs for the treatment of disease |
| EP4650003A2 (en) | 2019-06-28 | 2025-11-19 | IntraBio Ltd | Combination therapy with acetyl-leucine and miglustat for treating a lysosomal storage disease |
| US20230051742A1 (en) | 2020-01-13 | 2023-02-16 | Intrabio Ltd. | Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers |
-
2017
- 2017-06-14 GB GBGB1709459.0A patent/GB201709459D0/en not_active Ceased
-
2018
- 2018-06-25 AU AU2018284330A patent/AU2018284330B2/en active Active
- 2018-06-25 MD MDE20200433T patent/MD3638370T2/ro unknown
- 2018-06-25 PL PL18749124T patent/PL3638370T3/pl unknown
- 2018-06-25 HU HUE18749124A patent/HUE053089T2/hu unknown
- 2018-06-25 JP JP2020519196A patent/JP7130739B2/ja active Active
- 2018-06-25 WO PCT/IB2018/054676 patent/WO2018229738A1/en not_active Ceased
- 2018-06-25 ES ES18749124T patent/ES2847169T3/es active Active
- 2018-06-25 DK DK18749124.6T patent/DK3638370T3/da active
- 2018-06-25 SG SG11201912146RA patent/SG11201912146RA/en unknown
- 2018-06-25 SI SI201830195T patent/SI3638370T1/sl unknown
- 2018-06-25 PT PT187491246T patent/PT3638370T/pt unknown
- 2018-06-25 SM SM20210037T patent/SMT202100037T1/it unknown
- 2018-06-25 CN CN201880039532.2A patent/CN111093772B/zh active Active
- 2018-06-25 KR KR1020197038730A patent/KR102594130B1/ko active Active
- 2018-06-25 EP EP18749124.6A patent/EP3638370B1/en active Active
- 2018-06-25 IL IL271211A patent/IL271211B2/en unknown
- 2018-06-25 LT LTEP18749124.6T patent/LT3638370T/lt unknown
- 2018-06-25 RS RS20210046A patent/RS61481B1/sr unknown
- 2018-06-25 US US16/622,785 patent/US11471434B2/en active Active
- 2018-06-25 MX MX2019014784A patent/MX387909B/es unknown
- 2018-06-25 HR HRP20210108TT patent/HRP20210108T1/hr unknown
- 2018-06-25 MA MA49396A patent/MA49396B1/fr unknown
-
2019
- 2019-12-05 ZA ZA2019/08087A patent/ZA201908087B/en unknown
-
2021
- 2021-01-18 CY CY20211100033T patent/CY1123860T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019009443A (es) | Metodos para tratar la influenza. | |
| ZA202409975B (en) | Methods of treating schizophrenia | |
| MX2017010982A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| CO2018013293A2 (es) | Derivados de pirazolopirimidina como inhibidor de quinasa | |
| MX2023001193A (es) | Composicion de un anticuerpo inhibidor de masp-2 para usarse en el tratamiento de un padecimiento asociado con la activacion del complemento dependiente de masp-2. | |
| CO2017005034A2 (es) | Tratamiento de convulsiones con fosfatasa alcalina recombinante | |
| EA201390428A1 (ru) | Композиции и способы лечения легочной гипертензии | |
| MX2022007221A (es) | Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos. | |
| JOP20210033A1 (ar) | جرعة ليلية مزمنة من لاسميديتان للوقاية من الصداع النصفي | |
| CO2019009000A2 (es) | Combinaciones farmacéuticas para tratar cáncer | |
| AR112144A1 (es) | Compuestos para el tratamiento del sarcoma | |
| EA201791696A1 (ru) | Композиция для лечения веноокклюзионной болезни печени | |
| WO2015126930A3 (en) | Booster drug therapy for mycobacterium infections | |
| MY194448A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
| MX2024002581A (es) | Lou064 para el tratamiento de la esclerosis multiple. | |
| MX394782B (es) | Compuestos para el tratamiento de enfermedades asociadas con una disfunción mitocondrial. | |
| MX381311B (es) | Método para el tratamiento de prurito y/o comezón. | |
| MX2019014784A (es) | Tratamiento para la migra?a. | |
| EA201791525A3 (ru) | Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w | |
| MX2023008839A (es) | Composicion de liberacion tardia de linaclotida para uso en el tratamiento de trastornos gastrointestinales. | |
| AR099416A1 (es) | Terapia combinada para la hipertensión resistente | |
| ES2721003T3 (es) | Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis | |
| AR109209A1 (es) | Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas | |
| CL2017003143A1 (es) | Composición multi-péptido. | |
| EA201990443A1 (ru) | Новое применение n,n-бис-2 -меркаптоэтилизофталамида |